Appendix 4D

SIRTEX MEDICAL LIMITED

ABN 35 078 166 122

Interim report – half year ended 31 December 2014

(Previous corresponding period: half year ended 31 December 2013)

Results for announcement to the market

	% change	$ 000
Revenue from ordinary activities	up 37.3 %	80,452
Profit from ordinary activities after tax attributable to members	up 58.1 %	17,655
Total comprehensive income for the period attributable to members	up 58.9 %	18,191

Dividends (Distributions)

	2014	2013
Final dividend (paid on 22 October 2014 for financial year ended 30 June 2014)		
amount per security	14.0 cents	12.0 cents
franked amount per security	14.0 cents	12.0 cents
Interim dividend		
amount per security	Nil	Nil
franked amount per security	Nil	Nil

NTA Backing

	2014	2013
Net tangible asset backing per ordinary security	102.7 cents	93.6 cents

ASX / MEDIA RELEASE **18th February 2015**

SIRTEX PROFIT AFTER TAX UP 58 PER CENT FOR HALF YEAR

- **Net profit after tax (NPAT) increased 58.1 per cent to $17.7 million**
- **Global dose sales growth up 26.3 per cent to 4,950 units**
- **Revenue from sale of goods up 37.3 per cent to $80.5 million**
- **Cash flow from operating activities up 38.1 per cent to $21.9 million**
- **Fully Franked Dividend of 14 cents per share paid 22nd October 2014**

Sirtex Half Year Financial Results Summary

	1H 2015 $ '000	**1H 2014** $ '000	% change
Dose sales	4,950 units	3,919 units	+26.3%
Revenue from sale of goods	80,452	58,581	+37.3%
Profit before tax	23,925	14,594	+63.9%
Profit after tax	17,655	11,170	+58.1%
Cash at end of the half year*	55,455	47,850	+15.9%
Net cash flow from operations	21,948	15,892	+38.1%
Dividend per share paid	14 cents	12 cents	+16.7%
Capitalised Intangible Assets	10,255	9,899	+3.6%
Capitalised Tangible Assets	633	3,503	-81.9%

** Including cash on deposit for greater than 90 days.*

Sydney, Australia; 18th February 2015 - Sirtex Medical Limited (ASX: SRX) today announced half year results for the period ended 31st December 2014 confirming ongoing solid financial performance and continued growth in global demand for its SIR-Spheres® Y-90 resin microspheres targeted radiotherapy treatment for inoperable liver cancer.

Revenues from sale of goods improved 37.3 per cent to $80.5 million, an increase of $21.9 million over the previous corresponding period. Revenue growth was driven predominately by strong dose sales volume growth of 26.3 per cent. Revenue growth was further assisted by a price rise in the US market and the appreciation of the US dollar compared to the same period last year.

Net profit after tax (NPAT) for the half year increased 58.1 per cent to $17.7 million. Pre-tax profit increased 63.9 per cent from $14.6 million to $23.9 million. The effective tax rate was 26.2 per cent compared to 23.5 per cent in the same period last year.

Strong global sales growth continues

Global dose sales of SIR-Spheres microspheres to 4,950 units represented growth of 26.3 per cent compared to the same period last year.

The Americas achieved dose sales of 3,390. This represents an increase of 28.0 per cent with revenues growing 36.7 per cent (in US dollars) compared to the same period last year. Over the period, dose sales benefited from solid reimbursement achieved for SIR-Spheres microspheres in the US market, treating-hospitals footprint expansion and the investment made into the key US medical oncologist referral community. Recorded revenues accelerated significantly ahead of volumes as a result of a US$1,000 increase in the selling price of SIR-Spheres microspheres in the US market to US$16,000. SIR-Spheres microspheres were granted regulatory approval in Brazil during the reporting period with commercial dose sales recorded. Dose sales recorded in Canada, Argentina and Brazil were a very small percentage of the total recorded, given the early nature of our entry into these markets.

Europe, Middle East and Africa (EMEA) achieved dose sales of 1,120. This represents an increase of 28.1 per cent compared to the same period last year, with revenues growing 27.2 per cent (in Euro). Dose sales growth was assisted by the restoration of key UK market funding for SIR-Spheres microspheres through the Commissioning through Evaluation (CtE) process. Dose sales also benefited from: a return to growth in key Western European markets; new reimbursement in Israel; and a positive contribution from several other Middle Eastern markets. In the future, the recommendation of SIR-Spheres microspheres into the published European Society for Medical Oncology (ESMO) clinical guidelines for the treatment of metastatic colorectal cancer in patients who have failed to respond to available chemotherapy options, is also anticipated to deliver improved patient access to SIR-Spheres microspheres.

Asia Pacific (APAC) achieved dose sales of 440. This represents an increase of 10.8 per cent compared to the same period last year, with revenues growing 14.7 per cent. Dose sales and revenue growth were a reflection of solid growth in the key Australian market, sales mix benefits associated with direct market entry in several Asian jurisdictions, and price increases in several markets.

Sales and marketing

Sirtex continued to invest in sales and marketing, with expenses ahead of the SIRFLOX top-line data release in March 2015 up 39.0 per cent to $29.5 million from $21.2 million during the previous corresponding period.

The release of data from the SIRFLOX study will be a milestone for Sirtex and as previously disclosed, an additional $10 million will be invested over and above normal marketing expenditure during FY2015. The majority of this investment will be made in the second half of FY2015. These funds will support efforts to educate and inform members of the global medical community and facilitate their understanding and practical application of the study results.

Clinical investment

One of Sirtex's *2020Vision* key strategies is the major clinical studies program designed to give the medical community the level one data needed to make informed treatment decisions. Our goal is to provide data that conclusively demonstrates the efficacy of SIR-Spheres microspheres as an effective treatment option for patients at an earlier stage of their disease rather than as a treatment of last resort.

Global Clinical Studies Recruitment Progress in 1H FY2015

Study Name	Start	Total Patients	% Recruited @ 31 Dec 2013	% Recruited @ 30 June 2014	% Recruited @ 31 Dec 2014	Type of Liver Cancer(1)
SIRFLOX	2006	532	100%	100%	100%	mCRC
FOXFIRE FOXFIRE Global	2010	>560	68%	94%	100%(2)	mCRC
SARAH	2012	460	67%	92%	96%	HCC
SORAMIC	2010	375	53%	63%	75%	HCC
SIR*ve*NIB	2011	360	64%	69%	78%	HCC

(1) mCRC = Metastatic colorectal cancer or secondary liver cancer; HCC = Hepatocellular Carcinoma or primary liver cancer

(2) Completion of recruitment announced to ASX on 8th January 2015

Our investment directed at progressing the clinical studies increased 5.0 per cent to $12.0 million ($9.0 million capitalised and $3.0 million to P&L).

Preliminary results from Sirtex's SIRFLOX study in metastatic colorectal cancer (mCRC) are anticipated to be released in March 2015, with detailed results presented for peer review at the American Society of Clinical Oncology (ASCO) meeting from 29th May to 2nd June 2015.

Recruitment rates of the remaining clinical studies have accelerated in-line with our investment and growing awareness among the medical community of the potential offered by SIR-Spheres microspheres.

We anticipate the SARAH clinical study will complete patient recruitment during the first quarter of CY2015.

The FOXFIRE clinical study conducted in the UK by the University of Oxford completed recruitment in October 2014 with over 360 patients recruited across 32 centres. Sirtex completed recruitment of its FOXFIRE Global clinical study with over 200 patients recruited shortly after the end of the 1H FY2015. Collectively the SIRFLOX, FOXFIRE and FOXFIRE Global clinical studies recruited over 1,000 patients globally which will be combined to determine whether SIR-Spheres microspheres in combination with existing chemotherapy can increase Overall Survival (OS) in a clinically significant manner in patients with metastatic colorectal cancer when compared to patients receiving chemotherapy alone. We anticipate this data will be made available during the 1H of CY2017.

As our major studies approach full recruitment, Sirtex continues to investigate the potential uses of SIR-Spheres microspheres to treat cancers in other organs. Leading this program is our RESIRT study looking into the use of our therapy in renal cell carcinoma (kidney cancer) patients. During 1H FY2015 Sirtex announced an expansion of the study to include patients treated at higher radiation doses (beyond 200Gy) of SIR-Spheres microspheres. To date, the data has been very encouraging, and Sirtex plans to invest in a pivotal study for registration purposes during 2015.

Operating expenses

Sirtex's *2020Vision* also involves building the internal capabilities and capacity to meet future demand. During the reporting period total operating expenses increased 31.4 per cent to $46.4 million compared to $35.3 million in the previous corresponding period. Staff numbers grew 19.5 per cent to 226 during the period.

New product development

Sirtex maintained a strong focus on innovation and continued to develop a promising portfolio of new products towards commercialisation based on the success of our core technology platform.

Total R&D investment increased 3.7 per cent to $4.1 million ($1.2 million capitalised and $2.9 million to P&L) in the first half of FY2015. R&D expenses as a percentage of sales was 5.1 per cent compared to 6.8 per cent in the prior corresponding period.

Sirtex's SIR-Spheres Evolution Program focused on supporting our long term sales growth by delivering multiple enhancements to the administration and delivery of our current product.

Our new technologies, including carbon cage nanoparticles, coated nanoparticles, radioprotector and other novel platform technologies continued to make solid progress over the period.

Cash management and dividend

Cash flow from operating activities was up 38.1 per cent to $21.9 million. A fully franked dividend of 14 cents per share for FY2014 was paid on 22nd October 2014. This equated to a payment of $7.9 million and is Sirtex's sixth consecutive year of payments.

Sirtex remains debt free and had a cash balance of $55.5 million at the end of December 2014 compared to $47.8 million in December 2013.

Capital expenditure, excluding the capitalisation of intangible assets, for the period was $633,000 compared to $3.5 million for the previous corresponding period, reflecting the successful completion of our new manufacturing facility in Frankfurt, Germany. Sirtex anticipates first commercial sales from the new facility prior to the end of CY2015.

Foreign exchange

Foreign exchange movements continued to influence Sirtex's financial results as the Company earns over 95 per cent of revenue overseas. During the reporting period, the Australian dollar on average depreciated 3.4 per cent against the US dollar and appreciated

approximately 1 per cent against the Euro when compared to the corresponding period last year.

Outlook

Sirtex's business outlook in all markets remains positive and is driven by the large unmet global medical need for our liver cancer therapy.

The company's *2020Vision* is focused on ensuring the business is able to adapt and manage the potential opportunities and growth ahead. A key focus continues to be ensuring our readiness for the release of the SIRFLOX data and meeting the needs of our customers worldwide.

Sirtex remains committed to working together with our customers in the international medical community to make cancer a manageable chronic condition and improving the lives of thousands of people.

We believe our continued focus on operational excellence, the disciplined execution of our strategic plans, provision of the highest levels of service and support to our customers while continuing to invest in developing a promising new product pipeline all combine to create the foundation for long term growth and business success.

About SIR-Spheres® Y-90 Resin Microspheres

SIR-Spheres Y-90 resin microspheres are a medical device used in interventional oncology to deliver Selective Internal Radiation Therapy or SIRT (also known as radioembolisation), a proven technology for inoperable liver tumours that delivers substantial, targeted doses of radiation directly to the cancer. Key SIR-Spheres microspheres regulatory approvals include Pre-Market Approval (PMA) from the US FDA (2002), European Union (CE Mark) approval (2002) and Australian TGA approval (1998).

About Sirtex Medical

Sirtex Medical Limited (ASX:SRX) is an Australian-based global healthcare business working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres. Approximately 50,000 doses have been supplied to treat patients with liver cancer at more than 800 medical centres in over 40 countries. Please visit www.sirtex.com.

For further information please contact:

Investor Enquiries:

Mr Gilman Wong
CEO
Sirtex Medical Limited
Phone: +61 (02) 9964 8400

Dr Tom Duthy
Global Investor Relations Manager
Sirtex Medical Limited
Phone: +61 (0)2 9964 8427
Email: tduthy@sirtex.com

Media Enquiries:

Tim Allerton or Andrew Geddes
City PR
Phone: +61 (0)2 9267 4511

Interim Financial Report

FOR THE HALF-YEAR ENDED 31 DECEMBER 2014

SIRTEX MEDICAL LTD AND ITS CONTROLLED ENTITIES
ABN 35 078 166 122

Directors' Report	**2**
Auditor's Independence Declaration	**4**
Directors' Declaration	**5**
Independent Auditor's Review Report	**6**
Consolidated Statement of Profit or Loss and Other Comprehensive Income	**8**
Consolidated Statement of Financial Position	**9**
Consolidated Statement of Changes in Equity	**10**
Consolidated Statement of Cash Flows	**11**
Notes to the Financial Statements	**12**

Directors' Report

for the half-year ended 31 December 2014

Your Directors submit the financial report of the consolidated entity for the half-year ended 31 December 2014.

Directors

The names of Directors who held office during or since the end of the half-year:

R. Hill (Non-executive director, Chairman)

Dr J. Eady (Non-executive director, Deputy Chairman)

G. Boyce (Non-executive director)

G. Wong (Executive director, Chief Executive Officer)

Principal activities

Sirtex Medical Limited and its controlled entities ("Group") form a medical device group whose primary objective is to manufacture and to distribute effective liver cancer treatments utilising small particle technology to approved markets in Asia-Pacific, Europe and Middle East and North and South America.

Review of Operations

The Group's main product, called SIR-Spheres microspheres, is a targeted radioactive treatment for liver cancer. This treatment is called Selective Internal Radiation Therapy (SIRT) being a minimally invasive surgical procedure performed by an interventional radiologist. The SIR-Spheres microspheres lodge in the small blood vessels of the tumour where they destroy it from the inside over a short period while sparing the surrounding healthy tissue. During the half-year, the Group sold 4,950 doses worldwide representing less than 2% of the addressable market.

Dose sales for the half-year ended 31 December 2014 increased by 26.3% over the same period last financial year. The Americas with 3,390 doses achieved growth of 28.0%, the European and Middle East and Africa (EMEA) market with 1,120 doses achieved growth of 28.1%, and Asia Pacific (APAC) recorded 440 dose sales representing growth of 10.8%.

Sirtex recorded sales revenue of $80,452,000 for the half-year ended 31 December 2014. This represents an increase of 37.3% over the corresponding period last financial year ($58,581,000). The higher sales revenue growth compared to volume growth is a result of changes in geographic revenue mix with stronger growth in the high margin US region, and of positive foreign currency fluctuations, as the Australia Dollar depreciated against the US dollar during this financial period.

Gross margin increased to 84.3% for the half-year ended 31 December 2014, compared to 84.2% for the corresponding period last financial year. This was the result of improved efficiencies due to higher manufacturing volumes, a full year without a contract manufacturer, and a price increase in the US region at the end of the last financial year.

Profit before tax has improved 63.9% to $23,925,000 for the half-year ended 31 December 2014 (31 December 2013: $14,594,000), and Profit after tax has increased by 58.1% to $17,655,000 (31 December 2013: $11,170,000).

Directors' Report

for the half-year ended 31 December 2014

Earnings per share for the half-year ended 31 December 2014 have increased to $0.313 (2013: $0.199). During this half-year, a final dividend has been paid in respect of the previous financial year. The fully franked dividend was $0.14 per share, representing an increase of 16.7% over the previous dividend paid.

Net assets for the Group increased by 11.0% to $119,455,000 (30 June 2014: $107,583,000), mainly due to the investment of $10,255,000 (30 June 2014: $9,899,000) in internally generated intangible assets and $633,000 (30 June 2014: 3,503,000) in plant and equipment.

A significant part of the Group's clinical activities is focused on five major post-marketing clinical studies. Consistent with last year, expenses for these studies have been capitalised as they continue to satisfy the recognition criteria for AASB 138 Intangible Assets. Additions to capitalised costs incurred for these trials as well as for two smaller development projects during the half-year ended 31 December 2014 represent a total of $10,255,000 compared to $9,899,000 for the corresponding period of the previous financial year.

Rounding of Amounts

The consolidated entity has applied the relief available to it in ASIC Class Order 98/100 and accordingly certain amounts in the financial report and the directors' report have been rounded off to the nearest $1,000.

Events after Reporting Date

No matters or circumstances have arisen since the end of the half year, that has significantly affected, or may significantly affect, the operations of the Group, the results of those operations, or the state of affairs of the Group in future financial years.

Auditor's Independence Declaration

The lead auditor's independence declaration under section 307C of the Corporations Act 2001 is set out on page 4 for the half year ended 31 December 2014 and forms part of this report.

This report is signed in accordance with a resolution of the Board of Directors.

Gilman Wong
Director
18 February 2015

Level 17, 383 Kent Street
Sydney NSW 2000

Correspondence to:
Locked Bag Q800
QVB Post Office
Sydney NSW 1230

T +61 2 8297 2400
F +61 2 9299 4445
E info.nsw@au.gt.com
W www.grantthornton.com.au

Auditor's Independence Declaration
To The Directors of Sirtex Medical Limited

In accordance with the requirements of section 307C of the Corporations Act 2001, as lead auditor for the review of Sirtex Medical Limited for the half-year ended 31 December 2014, I declare that, to the best of my knowledge and belief, there have been:

a No contraventions of the auditor independence requirements of the Corporations Act 2001 in relation to the review; and

b No contraventions of any applicable code of professional conduct in relation to the review.

GRANT THORNTON AUDIT PTY LTD
Chartered Accountants

N J Bradley
Partner - Audit & Assurance

Sydney, 18 February 2015

Directors' Declaration **for the half-year ended 31 December 2014**

The directors of the company declare that:

1. The consolidated financial statements and notes, as set out on page 8 to 17, are in accordance with the Corporations Act 2001, including:
   a. complying with Accounting Standard AASB 134: Interim Financial Reporting; and
   b. giving a true and fair view of the consolidated entity's financial position as at 31 December 2014 and of its performance for the half year ended on that date.
2. In the directors' opinion there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors.

Gilman Wong
Director
18 February 2015

Level 17, 383 Kent Street
Sydney NSW 2000

Correspondence to:
Locked Bag Q800
QVB Post Office
Sydney NSW 1230

T +61 2 8297 2400
F +61 2 9299 4445
E info.nsw@au.gt.com
W www.grantthornton.com.au

Independent Auditor's Review Report
To the Members of Sirtex Medical Limited

We have reviewed the accompanying interim financial report of Sirtex Medical Limited ("Company"), which comprises the consolidated financial statements being the statement of financial position as at 31 December 2014, and the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the half-year ended on that date, notes comprising a statement or description of accounting policies, other explanatory information and the directors' declaration of the consolidated entity, comprising both the Company and the entities it controlled at the half year end or from time to time during the half-year.

Directors' responsibility for the interim financial report

The directors of Sirtex Medical Limited are responsible for the preparation of the interim financial report that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for such controls as the directors determine is necessary to enable the preparation of the interim financial report that is free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express a conclusion on the consolidated interim financial report based on our review. We conducted our review in accordance with the Auditing Standard on Review Engagements ASRE 2410 Review of a Financial Report Performed by the Independent Auditor of the Entity, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the interim financial report is not in accordance with the Corporations Act 2001 including: giving a true and fair view of the Sirtex Medical Limited consolidated entity's financial position as at 31 December 2014 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations

Regulations 2001. As the auditor of Sirtex Medical Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a interim financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we complied with the independence requirements of the Corporations Act 2001.

Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Sirtex Medical Limited is not in accordance with the Corporations Act 2001, including:

a giving a true and fair view of the consolidated entity's financial position as at 31 December 2014 and of its performance for the half-year ended on that date; and

b complying with Accounting Standard AASB 134 Interim Financial Reporting and Corporations Regulations 2001.

GRANT THORNTON AUDIT PTY LTD
Chartered Accountants



N J Bradley
Partner - Audit & Assurance

Sydney, 18 February 2015

Consolidated Statement of Profit or Loss and Other Comprehensive Income

for the half-year ended 31 December 2014

	Note	Consolidated 31 Dec 2014 $'000	Consolidated 31 Dec 2013 $'000
Revenue from the sale of goods		80,452	58,581
Cost of sales		(12,636)	(9,234)
Gross profit		**67,816**	**49,347**
Other revenue		1,016	1,035
Marketing expenses		(29,464)	(21,194)
Research expenses		(2,944)	(2,717)
Regulatory expenses		(582)	(424)
Quality assurance expenses		(835)	(701)
Clinical expenses		(2,963)	(2,782)
Medical expenses		(1,856)	(1,211)
Administration expenses		(7,732)	(6,249)
Impairment expenses		-	(1,007)
Foreign exchange gains		1,469	497
Profit before income tax expense	3	**23,925**	**14,594**
Income tax expense		(6,270)	(3,424)
Profit attributable to members of the parent entity		**17,655**	**11,170**
Other comprehensive income			
Items that may be reclassified subsequently to profit or loss			
Foreign currency translation (net of tax) of foreign operations		536	281
Total comprehensive income attributable to members of the parent entity		**18,191**	**11,451**
Earnings per share		**Cents**	**Cents**
Basic earnings per share	4	31.3	19.9
Diluted earnings per share	4	30.5	19.5

The financial statements should be read in conjunction with the accompanying notes

Consolidated Statement of Financial Position

as at 31 December 2014

	Note	Consolidated 31 Dec 14 $'000	Consolidated 30 Jun 14 $'000
CURRENT ASSETS			
Cash and cash equivalents		13,455	22,495
Other short-term deposits		42,000	30,000
Trade and other receivables		29,711	25,714
Inventories		1,457	1,678
Financial assets		1,247	1,276
Other assets		2,461	2,024
Current tax assets		-	554
Total - CURRENT ASSETS		**90,331**	**83,741**
NON-CURRENT ASSETS			
Property, plant and equipment		13,396	13,592
Intangible assets	2	57,715	47,364
Deferred tax assets		3,659	4,013
Total - NON-CURRENT ASSETS		**74,770**	**64,969**
TOTAL ASSETS		**165,101**	**148,710**
LIABILITIES			
CURRENT LIABILITIES			
Trade and other payables		14,146	14,657
Current tax liabilities		1,028	-
Short-term provisions		11,446	10,058
Total - CURRENT LIABILITIES		**26,620**	**24,715**
NON-CURRENT LIABILITIES			
Long-term provisions		1,256	874
Deferred tax liabilities		17,770	15,538
Total - NON-CURRENT LIABILITIES		**19,026**	**16,412**
TOTAL LIABILITIES		**45,646**	**41,127**
NET ASSETS		**119,455**	**107,583**
EQUITY			
Issued capital		26,426	24,893
Reserves		3,718	3,121
Retained earnings		89,311	79,569
TOTAL EQUITY		**119,455**	**107,583**

The financial statements should be read in conjunction with the accompanying notes

Consolidated Statement of Changes in Equity

for the half-year ended 31 December 2014

	Ordinary Shares	Share rights Reserve	FX Translation Reserve	Retained Profits	Total
	$'000	$'000	$'000	$'000	$'000
Balance at 1 July 2013	**23,521**	**1,998**	**185**	**62,434**	**88,138**
Total comprehensive income for the period	-	-	281	11,170	11,451
Ordinary shares issued	708	(708)	-	-	-
Deferred tax on performance rights	809	-	-	-	809
Contribution to Performance Rights Reserve	-	580	-	-	580
Dividends paid or provided for	-	-	-	(6,733)	(6,733)
Balance at 31 December 2013	**25,038**	**1,870**	**466**	**66,871**	**94,245**
Balance at 1 July 2014	**24,893**	**2,774**	**347**	**79,569**	**107,583**
Total comprehensive income for the period	-	-	536	17,655	18,191
Ordinary shares issued	948	(948)	-	-	-
Deferred tax on performance rights	677	-	-	-	677
Treasury shares	(92)	-	-	-	(92)
Contribution to Performance Rights Reserve	-	1,009	-	-	1,009
Dividends paid or provided for	-	-	-	(7,913)	(7,913)
Balance at 31 December 2014	**26,426**	**2,835**	**883**	**89,311**	**119,455**

The financial statements should be read in conjunction with the accompanying notes

Consolidated Statement of Cash Flows

for the half-year ended 31 December 2014

	Consolidated	
	31 Dec 2014	**31 Dec 2013**
	$'000	**$'000**
CASH FLOWS FROM OPERATING ACTIVITIES		
Receipts from customers	75,745	59,082
Payments to suppliers and employees	(52,367)	(39,158)
Interest received	1,167	1,162
Net income tax paid	(2,597)	(5,194)
Net cash provided by operating activities	**21,948**	**15,892**
CASH FLOWS FROM INVESTING ACTIVITIES		
Investment in / Purchase of short-term deposits	(12,000)	(2,000)
Purchase of plant and equipment	(633)	(3,503)
Purchase of intangible assets	(187)	-
Internally generated intangible assets	(10,255)	(9,899)
Net cash used in investing activities	**(23,075)**	**(15,402)**
CASH FLOWS FROM FINANCING ACTIVITIES		
Payment of dividends	(7,913)	(6,733)
Net cash used in financing activities	**(7,913)**	**(6,733)**
Increase / (Decrease) in cash held	**(9,040)**	**(6,243)**
Cash at beginning of the financial period (1)	**22,495**	**20,094**
Cash at end of the financial period (1)	**13,455**	**13,851**

(1) Cash at the end of the financial period excludes term deposits held with a maturity date of greater than 90 days after the end of the financial period. These are described as “other short term deposits” in the Consolidated Statement of Financial Position.

The financial statements should be read in conjunction with the accompanying notes

Notes to the Financial Statements

for the half-year ended 31 December 2014

NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of preparation

These general purpose financial statements for the interim half-year reporting period ended 31 December 2014 have been prepared in accordance with requirements of the *Corporations Act 2001* and Australian Accounting Standards including AASB 134: Interim Financial Reporting, and are presented in Australian dollar ($), which is the functional currency of the parent company.

This interim financial report is intended to provide users with an update on the latest annual financial statements of Sirtex Medical Limited and its controlled entities (the Group). They do not include all of the information required in annual financial statements in accordance with Australian Accounting Standards, and should be read in conjunction with the consolidated financial statements of the Group for the year ended 30 June 2014 and any public announcements made by the Group during the half-year in accordance with continuous disclosure requirements arising under the Australian Stock Exchange Listing Rules and the *Corporations Act 2001*.

Estimates

When preparing the interim financial statements, management undertakes a number of judgements, estimates and assumptions about recognition and measurement of assets, liabilities, income and expenses. The actual results may differ from the judgements, estimates and assumptions made by management. The judgements, estimates and assumptions made during the period ended 31 December 2014 were the same as those applied in the Group's last financial statements for the year ended 30 June 2014.

These financial statements were authorised for issue by the Board of Directors on 18 February 2015.

NOTE 2: INTANGIBLE ASSETS

Internally generated intangible assets

Internally generated intangible assets include five major Phase IV post-marketing clinical trials and two development projects aiming to improve the ease of use of Sir-Spheres microspheres. As these activities satisfy the recognition criteria as set out below, expenses incurred during the half year for these activities have been classified as internally generated intangible assets and capitalised in the Statement of Financial Position, for a total of $10,255,174.

Expenditure during the research phase of a project is recognised as an expense when incurred. Development costs are capitalised if, and only if all of the following is demonstrated:

- The technical feasibility of completing the intangible asset so that it will be available for use or for sale
- The intention to complete the intangible asset and to use it or sell it
- The ability to use or to sell the intangible asset
- The intangible asset will generate future economic benefits
- Adequate technical, financial, and other resources to complete the development and to use or sell the intangible asset are available
- The expenditure attributable to the intangible asset during its development can be reliably measured

Following the initial recognition of the development expenditure, the cost model is applied requiring the assets to be carried at cost less accumulated impairment losses. Current capitalised development costs are to be amortised over 7 years.

The Consolidated Entity uses its judgment in continually assessing whether development expenditure meet the recognition criteria on an intangible asset.

At 31 December 2014, the assessment of all development activities resulted in the recognition of certain development expenditure as an internally generated intangible asset.

The carrying value of an intangible asset arising from development costs is tested for impairment annually when the asset is not yet available for use or more frequently when an indicator of impairment arises during the reporting period.

	Consolidated	
	31 Dec 14 $'000	30 Jun 14 $'000
Total intangible assets		
At cost	61,436	50,996
Accumulated amortisation	(3,721)	(3,632)
Net carrying amount	57,715	47,364
Movements in carrying amounts		
Total intangible assets		
Carrying amount at beginning	47,364	28,376
Additions	10,442	19,175
Amortisation expense	(91)	(187)
Carrying amount at end	57,715	47,364

NOTE 3: PROFIT FOR THE PERIOD

	Consolidated	
	31 Dec 14 $'000	31 Dec 13 $'000
Profit before income tax includes the following items of income / (expenses):		
Cost of sales	(12,636)	(9,234)
Bad and doubtful debts expense	115	(1,005)
Depreciation and amortisation of		
plant and equipment	(831)	(663)
intangible assets	(91)	(96)
Operating lease expenses		
minimum lease payments	(1,250)	(596)
Foreign exchange gains / (losses)		
Realised foreign exchange gains / (losses)	549	(54)
Unrealised foreign exchange gains / (losses)	920	551

Notes to the Financial Statements

for the half-year ended 31 December 2014

NOTE 4: EARNINGS PER SHARE

	Consolidated	
	31 Dec 14 $	31 Dec 13 $
(a) Basic earnings per share		
Profit from continuing operations attributable to equity holders	17,655,000	11,170,000
Weighted average number of shares used in the calculation of basic earnings per share	56,491,707	55,768,136
Add to number of shares used in the calculation of diluted earnings per share: Effect of potential conversion to ordinary shares under the Executive Performance and the Non-Executive Directors' Rights Plan	1,479,770	1,402,688
(b) Diluted earnings per share		
Profit from continuing operations attributable to equity holders	17,655,000	11,170,000
Weighted average number of shares used in the calculation of diluted earnings per share	57,971,477	57,170,824

NOTE 5: SHARE CAPITAL

During the period ended 31 December 2014, a total of 421,792 shares were issued as a result of the exercise of performance rights vested. The weighted average share price at the date of issue was $19.22 during the first six months (2013: $12.33). Each share has the same right to receive dividends and the repayment of capital and represents one vote at the shareholders' meeting. Shares issued and authorised are summarised as follows:

	Consolidated	
	6 months to 31 Dec 14	Year to 30 Jun 14
Shares issued and fully paid:		
Beginning of the period	56,108,439	55,768,136
Issued under share-based payment plans	421,792	340,303
Shares issued and fully paid	**56,530,231**	**56,108,439**
Total shares authorised at the end of the period	**56,530,231**	**56,108,439**

NOTE 6: DIVIDENDS

	Consolidated	
	31 Dec 14 $'000	31 Dec 13 $'000
Distributions paid/provided for		
Fully franked ordinary dividend paid on 22 October 2014 of 14 cents (2013: 12 cents) per share	7,913	6,733

NOTE 7: OPERATING SEGMENT

Identification of reportable segments
The Group has identified its operating segments based on the internal reports that are reviewed and used by the Board of Directors in assessing performance and determining the allocation of resources.

The Group is managed primarily on the basis of regional markets which have different structures and performance as assessment criteria. Operating segments are therefore determined on the same basis. The three regional markets currently serviced by the group are Asia Pacific, North and South America (Americas) and Europe, Middle East, and Africa.

As the group manufactures and distributes only one product, identical for each of the three regional markets, no further segmentation across products or services is made.

Basis of accounting for purposes of reporting by operating segments

Accounting policies adopted
Unless stated otherwise, all amounts reported to the Board of Directors with respect to operating segments are determined in accordance with accounting policies that are consistent to those adopted in the annual financial statements of the Group.

Inter-segment transactions
An internally determined transfer price is set for all inter-entity sales. This price is re-set annually and is based on what would be realised in the event the sale was made to an external party at arm's length. All such transactions are eliminated on consolidation for the Group's financial statements.

Inter-segment loans payable and receivable are initially recognised at the consideration received net of transaction costs. If inter-segment loans are not on commercial terms, these are not adjusted to fair value based on market interest rates. This policy represents a departure from that applied to the statutory financial statements.

Segment assets
Where an asset is used across multiple segments, the asset is allocated to the segment that received the majority of economic value from the asset. In the majority of instances, segment assets are clearly identifiable on the basis of their nature and physical location.

Segment liabilities
Liabilities are allocated to segments where there is direct nexus between the incurrence of the liability and the operations of the segment. Borrowings and tax liabilities are generally considered to relate to the Group as a whole and are not allocated. Segment liabilities include trade and other payables and certain direct borrowings.

Segment performance

Segment revenue

For 6 months to	External Sales		Inter-segment(s)		Other		Total	
31 Dec 14, and	2014	2013	2014	2013	2014	2013	2014	2013
31 Dec 13	$'000	$'000	$'000	$'000	$'000	$'000	$'000	$'000
Asia Pacific	3,207	2,795	67,787	51,473	946	1,034	71,940	55,302
Americas	61,220	43,100	5,759	4,417	1	-	66,980	47,517
Europe, Middle East, and Africa	16,025	12,686	495	899	69	-	16,589	13,585
Total of all segments							**155,509**	**116,404**
Eliminations							(74,041)	(56,788)
Unallocated							-	-
Consolidated							**81,468**	**59,616**

NOTE 7: OPERATING SEGMENT (continued)

Segment net profit before tax

	2014 $'000	2013 $'000
Asia Pacific	22,967	16,426
Americas	789	(201)
Europe, Middle East, and Africa	169	(1,631)
Total of all segments	**23,925**	**14,594**
Eliminations	-	-
Profit before income tax expense	**23,925**	**14,594**
Income tax expense	(6,270)	(3,424)
Profit after income tax expense	**17,655**	**11,170**

Segment assets and liabilities

	Assets		Liabilities	
	31 Dec 14 $'000	30 Jun 14 $'000	31 Dec 14 $'000	30 Jun 14 $'000
Asia Pacific	218,346	188,769	91,252	72,525
Americas	36,659	31,622	24,306	20,062
Europe, Middle East, and Africa	17,964	17,746	14,130	14,141
Total of all segments	**272,969**	**238,137**	**129,688**	**106,728**
Eliminations	(107,868)	(89,427)	(84,042)	(65,601)
Consolidated	**165,101**	**148,710**	**45,646**	**41,127**

Other segment information

	Asia Pacific		North America		Europe	
	2014 $'000	2013 $'000	2014 $'000	2013 $'000	2014 $'000	2013 $'000
Acquisition of segment assets						
- Plant and equipment	358	306	127	483	148	2,713
- Intangibles	187	-	-	-	-	-
Depreciation and amortisation of segment assets						
- Plant and equipment	486	416	212	200	133	47
- Intangibles	91	94	-	-	-	2

NOTE 8: CONTINGENT LIABILITIES

The Group does not have any contingent liability as at 31 December 2014.

NOTE 9: EVENTS AFTER REPORTING DATE

No matters or circumstances have arisen since the end of the financial half year which significantly affected or may significantly affect the operations of the Group, the results of those operations, or the state of affairs of the Group in future financial years.